GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Puma Biotechnology Inc (NAS:PBYI) » Definitions » EV-to-EBIT

Puma Biotechnology (Puma Biotechnology) EV-to-EBIT : 6.88 (As of Apr. 25, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Puma Biotechnology EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Puma Biotechnology's Enterprise Value is $247.7 Mil. Puma Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $36.0 Mil. Therefore, Puma Biotechnology's EV-to-EBIT for today is 6.88.

The historical rank and industry rank for Puma Biotechnology's EV-to-EBIT or its related term are showing as below:

PBYI' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.15   Med: -7.49   Max: 21.29
Current: 6.88

During the past 13 years, the highest EV-to-EBIT of Puma Biotechnology was 21.29. The lowest was -40.15. And the median was -7.49.

PBYI's EV-to-EBIT is ranked better than
51.58% of 444 companies
in the Biotechnology industry
Industry Median: 8.05 vs PBYI: 6.88

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Puma Biotechnology's Enterprise Value for the quarter that ended in Dec. 2023 was $221.9 Mil. Puma Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $36.0 Mil. Puma Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 16.23%.


Puma Biotechnology EV-to-EBIT Historical Data

The historical data trend for Puma Biotechnology's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Puma Biotechnology EV-to-EBIT Chart

Puma Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.81 -9.59 -9.98 19.03 6.16

Puma Biotechnology Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.03 10.60 18.37 8.55 6.16

Competitive Comparison of Puma Biotechnology's EV-to-EBIT

For the Biotechnology subindustry, Puma Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Puma Biotechnology's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Puma Biotechnology's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Puma Biotechnology's EV-to-EBIT falls into.



Puma Biotechnology EV-to-EBIT Calculation

Puma Biotechnology's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=247.669/36.004
=6.88

Puma Biotechnology's current Enterprise Value is $247.7 Mil.
Puma Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Puma Biotechnology  (NAS:PBYI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Puma Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=36.004/221.861644
=16.23 %

Puma Biotechnology's Enterprise Value for the quarter that ended in Dec. 2023 was $221.9 Mil.
Puma Biotechnology's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $36.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Puma Biotechnology EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Puma Biotechnology's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Puma Biotechnology (Puma Biotechnology) Business Description

Traded in Other Exchanges
N/A
Address
10880 Wilshire Boulevard, Suite 2150, Los Angeles, CA, USA, 90024
Puma Biotechnology Inc is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The company in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. FDA in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the US as NERLYNX.
Executives
Alan H Auerbach director, 10 percent owner, officer: PRESIDENT, CEO & SECRETARY 10940 WILSHIRE BLVD. SUITE 600, LOS ANGELES CA 90024
Alvin F Wong officer: Chief Scientific Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Maximo F Nougues officer: Chief Financial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Jeffrey Jerome Ludwig officer: Chief Commercial Officer C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Douglas M Hunt officer: See Remarks C/O PUMA BIOTECHNOLOGY,INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Michael Patrick Miller director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN 4 L2
Adrian Senderowicz director C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Troy Edward Wilson director C/O KURA ONCOLOGY, INC., 12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO CA 92130
Allison Dorval director C/O INSULET CORPORATION, 600 TECHNOLOGY PARK DRIVE, SUITE 200, BILLERICA MA 01821
Brian M Stuglik director C/O VERASTEM, INC., 117, NEEDHAM MA 02494
Jay M Moyes director
Alessandra Cesano director 700 BALTIC CIRCLE, SUITE 716, REDWOOD CITY CA 94065
Ann Calby Miller director C/O INOVIO PHARMACEUTICALS, INC., 660 W. GERMANTOWN PIKE, SUITE 110, PLYMOUTH MEETING PA 19462
Richard Paul Bryce officer: SR VP, CLINICAL RESEARCH & DEV C/O PUMA BIOTECHNOLOGY, INC., 10880 WILSHIRE BOULEVARD, SUITE 2150, LOS ANGELES CA 90024
Hugh O'dowd director C/O NEON THERAPEUTICS, INC., 40 ERRIE STREET SUITE 110, CAMBRIDGE MA 02139

Puma Biotechnology (Puma Biotechnology) Headlines